An observational study on the effect of l-ornithine-l-aspartate (LOLA) on the gut microbiome in liver cirrhosis. A single center phase 4 study
Clinical Nutrition · 2026
DOI: 10.1016/j.clnu.2025.11.007 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Nutrition, 2026. Verfasst von Daniel Habich und 16 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biomarker Research in Medicine, Graz, Austria. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Liver Cirrhosis, Dipeptides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission, European Regional Development Fund, BioTechMed-Graz.
Abstract (Originalsprache)
BACKGROUND & AIMS: Liver cirrhosis is associated with gut microbiome dysbiosis, intestinal inflammation and gut barrier dysfunction, contributing to reduced quality of life and the development of complications. We showed in a retrospective study that l-ornithine-l-aspartate (LOLA) was associated with improvement in taxonomic composition of the microbiome. Here we prospectively studied the influence of LOLA on the gut microbiome, quality of life, sarcopenia and the gut barrier. METHODS: In this phase 4 study, patients with liver cirrhosis and hepatic encephalopathy grade 0-2 received LOLA 18 g/day orally for 3 months. We studied faecal microbiome composition (primary endpoint abundance of the genus Flavonifractor), microbiome function, quality of life, serum ammonia levels, sarcopenia and frailty, biomarkers of the gut liver axis and the stool, serum and urine metabolome. RESULTS: We screened 258 patients with liver cirrhosis, included 65, of whom 52 patients (40 % female, age 62 (58; 65)) completed the study. LOLA intake decreased the abundance of the genus Romboutsia, increased the abundance of the genus Enterococcus, but did not alter other microbiome parameters. LOLA improved one out of 8 dimension of quality of life (vitality) and decreased serum ammonia concentrations. The subgroup of patients with improved ammonia concentrations responded with a halt in further muscle mass declined over the study period. Diamine oxidase, a marker of intestinal mucosal condition, decreased and LPS binding protein increased. Metabolomic analysis indicated an increase in alanine concentration. CONCLUSIONS: LOLA improved one quality of life dimension (vitality) and biomarker of the gut-liver axis, altered innate immune response, faecal microbiome and metabolome. LOLA prevented muscle loss only in patients with elevated ammonia concentrations at baseline. LOLA may therefore be a useful adjunct treatment to improve quality of life in cirrhosis and a promising intervention for muscle loss prevention in hyperammonemic patients. CLINICAL TRIALS REGISTRATION NUMBER: clinicaltrials.gov NCT05737030. IMPACT AND IMPLICATION: We conducted a 12-week prospective cohort study to test the effect of the ammonia lowering drug l-ornithine-l-aspartate (LOLA) on the gut microbiome, biomarkers along the gut-liver-axis, muscle health and quality of life in patients with liver cirrhosis and hepatic encephalopathy. Although our primary endpoint was not reached, LOLA slightly altered microbiome composition and function and improved vitality, a clinically relevant patient reported outcome parameter. LOLA also improved biomarkers for the gut-liver-axis, innate immune response and prevented muscle loss in patients with elevated ammonia levels at baseline. LOLA may therefore be a useful adjunct treatment to improve quality of life in cirrhosis and to prevent muscle loss in hyperammonemic patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Biomarker Research in Medicine, Graz, Austria.
- Center for Biomarker Research in Medicine, Graz, Austria; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
- Department of Medical Chemistry, Otto Loewi Research Center for Vascular Biology, Medical University of Graz, Graz, Austria; BioTechMed-Graz, Graz, Austria.
- Department of Medical Chemistry, Otto Loewi Research Center for Vascular Biology, Medical University of Graz, Graz, Austria.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; BioTechMed-Graz, Graz, Austria.
Förderung
- European Commission
- European Regional Development Fund
- BioTechMed-Graz
- Austrian Science Fund
- Merz Pharmaceuticals
- Österreichische Forschungsförderungsgesellschaft
Zitieren
APA
Habich, D., Horvath, A., Feldbacher, N., Rebol, L., Nepel, M., Madl, T., Habisch, H. J., Baumann-Durchschein, F., Fürst, S., Plank, J., Rainer, F., Spindelböck, W., Stauber, R. E., Tatscher, E., Wagner, M., Zollner, G., & Stadlbauer, V. (2026). An observational study on the effect of l-ornithine-l-aspartate (LOLA) on the gut microbiome in liver cirrhosis. A single center phase 4 study. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2025.11.007
Vancouver
Habich D, Horvath A, Feldbacher N, Rebol L, Nepel M, Madl T, et al. An observational study on the effect of l-ornithine-l-aspartate (LOLA) on the gut microbiome in liver cirrhosis. A single center phase 4 study. Clinical Nutrition. 2026. doi:10.1016/j.clnu.2025.11.007
BibTeX
@article{Habich2026,
author = {Habich, Daniel and Horvath, Angela and Feldbacher, Nicole and Rebol, Lavra and Nepel, Maximilian and Madl, Tobias and Habisch, Hans-Jörg and Baumann-Durchschein, Franziska and Fürst, Stefan and Plank, Johannes and Rainer, Florian and Spindelböck, Walter and Stauber, Rudolf E and Tatscher, Elisabeth and Wagner, Martin and Zollner, Gernot and Stadlbauer, Vanessa},
title = {An observational study on the effect of l-ornithine-l-aspartate (LOLA) on the gut microbiome in liver cirrhosis. A single center phase 4 study},
journal = {Clinical Nutrition},
year = {2026},
doi = {10.1016/j.clnu.2025.11.007}
}
EUVIMED